Clinical Trials Directory

Trials / Completed

CompletedNCT01893528

Study to Assess the Safety and Tolerability of Ascending Single Doses of REGN2009 in Healthy Volunteers

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
49 (actual)
Sponsor
Regeneron Pharmaceuticals · Industry
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Accepted

Summary

This is a phase 1, randomized, double-blind, placebo-controlled first-in-human (FIH) study to assess the safety and tolerability of ascending single doses of REGN2009 administered to healthy volunteers.

Conditions

Interventions

TypeNameDescription
DRUGREGN2009
OTHERplacebo

Timeline

Start date
2013-06-01
Primary completion
2014-09-01
Completion
2014-09-01
First posted
2013-07-09
Last updated
2014-11-10

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT01893528. Inclusion in this directory is not an endorsement.

Study to Assess the Safety and Tolerability of Ascending Single Doses of REGN2009 in Healthy Volunteers (NCT01893528) · Clinical Trials Directory